CytoDyn Files an IND and a Phase 2 Protocol with the FDA for the Treatment of NASH with Leronlimab

    NEXT STORY
    Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses
    PREV STORY
    Opthea’s Phase 2b Study of OPT-302 in Wet AMD to be Presented in Late-Breaking Session of EURETINA
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Enhanced MuScreen™ Platform Revolutionizes Preclinical Development of Immunotherapeutics

    SAN DIEGO, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of ...

    author_avatar
    NASDAQ Market News

    Air Methods’ EVP, Chris Myers, Appointed to Air Ambulance and Patient Billing Advisory Committee

    author_avatar
    NASDAQ Market News

    Immunocore announces dosing of first patient with fourth ImmTAC®

    author_avatar
    NASDAQ Market News